CTOs on the Move


 
GyPSii is a Warwick, RI-based company in the Software and Internet sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.gypsii.com
  • 175 Metro Center Blvd Ste 4
    Warwick, RI USA 02886
  • Phone: 401.921.5184

Executives

Name Title Contact Details

Similar Companies

Vela

Vela is a leading independent provider of trading and market access technology for global multi-asset electronic trading. Our software enables clients to successfully execute on their trading strategies and manage risk across multiple fragmented markets, liquidity pools, and data sources. We help firms successfully differentiate and innovate in an ever-changing, increasingly-regulated and fiercely-competitive landscape, while also reducing total cost of ownership. Velas ticker plant, execution gateways, trading platform, and risk and analytics software deliver a unique, ultra-low latency technology stack for electronic low-touch and Direct Market Access (DMA) execution and pricing. We leverage the latest innovations in technology to deliver cutting-edge performance, features and reliability. Our modular stack is accessed through a single set of trading, data and risk APIs and can be delivered as-a-Service from multiple co-location data centers globally. With access to more than 250 venues, Vela provides global coverage across all major asset classes. Clients are supported by an award-winning team of technical and business experts available 24x7 from our multiple offices in the US, Europe, and Asia. Velas clients include traders, market makers, brokers, banks, investment firms, exchanges, and other market participants.

Nolo

The Nolo Network: With over 50 web properties, the Nolo Network is one of the web’s largest libraries of consumer-friendly legal information – all available for free. With oversight from Nolo’s editorial team, we strive to deliver free legal informat...

Tidepool

Tidepool is an open source, not-for-profit effort to build an open data platform and better applications that reduce the burden of Type 1 Diabetes.